Cargando…

A Shared Nephroprotective Mechanism for Renin-Angiotensin-System Inhibitors, Sodium-Glucose Co-Transporter 2 Inhibitors, and Vasopressin Receptor Antagonists: Immunology Meets Hemodynamics

A major paradigm in nephrology states that the loss of filtration function over a long time is driven by a persistent hyperfiltration state of surviving nephrons. This hyperfiltration may derive from circulating immunological factors. However, some clue about the hemodynamic effects of these factors...

Descripción completa

Detalles Bibliográficos
Autores principales: Capolongo, Giovanna, Capasso, Giovambattista, Viggiano, Davide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999762/
https://www.ncbi.nlm.nih.gov/pubmed/35409276
http://dx.doi.org/10.3390/ijms23073915
_version_ 1784685267630686208
author Capolongo, Giovanna
Capasso, Giovambattista
Viggiano, Davide
author_facet Capolongo, Giovanna
Capasso, Giovambattista
Viggiano, Davide
author_sort Capolongo, Giovanna
collection PubMed
description A major paradigm in nephrology states that the loss of filtration function over a long time is driven by a persistent hyperfiltration state of surviving nephrons. This hyperfiltration may derive from circulating immunological factors. However, some clue about the hemodynamic effects of these factors derives from the effects of so-called nephroprotective drugs. Thirty years after the introduction of Renin-Angiotensin-system inhibitors (RASi) into clinical practice, two new families of nephroprotective drugs have been identified: the sodium-glucose cotransporter 2 inhibitors (SGLT2i) and the vasopressin receptor antagonists (VRA). Even though the molecular targets of the three-drug classes are very different, they share the reduction in the glomerular filtration rate (GFR) at the beginning of the therapy, which is usually considered an adverse effect. Therefore, we hypothesize that acute GFR decline is a prerequisite to obtaining nephroprotection with all these drugs. In this study, we reanalyze evidence that RASi, SGLT2i, and VRA reduce the eGFR at the onset of therapy. Afterward, we evaluate whether the extent of eGFR reduction correlates with their long-term efficacy. The results suggest that the extent of initial eGFR decline predicts the nephroprotective efficacy in the long run. Therefore, we propose that RASi, SGLT2i, and VRA delay kidney disease progression by controlling maladaptive glomerular hyperfiltration resulting from circulating immunological factors. Further studies are needed to verify their combined effects.
format Online
Article
Text
id pubmed-8999762
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89997622022-04-12 A Shared Nephroprotective Mechanism for Renin-Angiotensin-System Inhibitors, Sodium-Glucose Co-Transporter 2 Inhibitors, and Vasopressin Receptor Antagonists: Immunology Meets Hemodynamics Capolongo, Giovanna Capasso, Giovambattista Viggiano, Davide Int J Mol Sci Review A major paradigm in nephrology states that the loss of filtration function over a long time is driven by a persistent hyperfiltration state of surviving nephrons. This hyperfiltration may derive from circulating immunological factors. However, some clue about the hemodynamic effects of these factors derives from the effects of so-called nephroprotective drugs. Thirty years after the introduction of Renin-Angiotensin-system inhibitors (RASi) into clinical practice, two new families of nephroprotective drugs have been identified: the sodium-glucose cotransporter 2 inhibitors (SGLT2i) and the vasopressin receptor antagonists (VRA). Even though the molecular targets of the three-drug classes are very different, they share the reduction in the glomerular filtration rate (GFR) at the beginning of the therapy, which is usually considered an adverse effect. Therefore, we hypothesize that acute GFR decline is a prerequisite to obtaining nephroprotection with all these drugs. In this study, we reanalyze evidence that RASi, SGLT2i, and VRA reduce the eGFR at the onset of therapy. Afterward, we evaluate whether the extent of eGFR reduction correlates with their long-term efficacy. The results suggest that the extent of initial eGFR decline predicts the nephroprotective efficacy in the long run. Therefore, we propose that RASi, SGLT2i, and VRA delay kidney disease progression by controlling maladaptive glomerular hyperfiltration resulting from circulating immunological factors. Further studies are needed to verify their combined effects. MDPI 2022-04-01 /pmc/articles/PMC8999762/ /pubmed/35409276 http://dx.doi.org/10.3390/ijms23073915 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Capolongo, Giovanna
Capasso, Giovambattista
Viggiano, Davide
A Shared Nephroprotective Mechanism for Renin-Angiotensin-System Inhibitors, Sodium-Glucose Co-Transporter 2 Inhibitors, and Vasopressin Receptor Antagonists: Immunology Meets Hemodynamics
title A Shared Nephroprotective Mechanism for Renin-Angiotensin-System Inhibitors, Sodium-Glucose Co-Transporter 2 Inhibitors, and Vasopressin Receptor Antagonists: Immunology Meets Hemodynamics
title_full A Shared Nephroprotective Mechanism for Renin-Angiotensin-System Inhibitors, Sodium-Glucose Co-Transporter 2 Inhibitors, and Vasopressin Receptor Antagonists: Immunology Meets Hemodynamics
title_fullStr A Shared Nephroprotective Mechanism for Renin-Angiotensin-System Inhibitors, Sodium-Glucose Co-Transporter 2 Inhibitors, and Vasopressin Receptor Antagonists: Immunology Meets Hemodynamics
title_full_unstemmed A Shared Nephroprotective Mechanism for Renin-Angiotensin-System Inhibitors, Sodium-Glucose Co-Transporter 2 Inhibitors, and Vasopressin Receptor Antagonists: Immunology Meets Hemodynamics
title_short A Shared Nephroprotective Mechanism for Renin-Angiotensin-System Inhibitors, Sodium-Glucose Co-Transporter 2 Inhibitors, and Vasopressin Receptor Antagonists: Immunology Meets Hemodynamics
title_sort shared nephroprotective mechanism for renin-angiotensin-system inhibitors, sodium-glucose co-transporter 2 inhibitors, and vasopressin receptor antagonists: immunology meets hemodynamics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999762/
https://www.ncbi.nlm.nih.gov/pubmed/35409276
http://dx.doi.org/10.3390/ijms23073915
work_keys_str_mv AT capolongogiovanna asharednephroprotectivemechanismforreninangiotensinsysteminhibitorssodiumglucosecotransporter2inhibitorsandvasopressinreceptorantagonistsimmunologymeetshemodynamics
AT capassogiovambattista asharednephroprotectivemechanismforreninangiotensinsysteminhibitorssodiumglucosecotransporter2inhibitorsandvasopressinreceptorantagonistsimmunologymeetshemodynamics
AT viggianodavide asharednephroprotectivemechanismforreninangiotensinsysteminhibitorssodiumglucosecotransporter2inhibitorsandvasopressinreceptorantagonistsimmunologymeetshemodynamics
AT capolongogiovanna sharednephroprotectivemechanismforreninangiotensinsysteminhibitorssodiumglucosecotransporter2inhibitorsandvasopressinreceptorantagonistsimmunologymeetshemodynamics
AT capassogiovambattista sharednephroprotectivemechanismforreninangiotensinsysteminhibitorssodiumglucosecotransporter2inhibitorsandvasopressinreceptorantagonistsimmunologymeetshemodynamics
AT viggianodavide sharednephroprotectivemechanismforreninangiotensinsysteminhibitorssodiumglucosecotransporter2inhibitorsandvasopressinreceptorantagonistsimmunologymeetshemodynamics